Bernardo H. L. Goulart, MD, MS
Bernardo Goulart, MD, MS decided to become a doctor because his father was an internist. “His role model definitely influenced my choice to become a physician,” Goulart says. “I have also found in medicine a niche for two of my main psychological drivers of professional interest: the first driver is my fascination for human biology and human responses to pathological processes, especially the biology of cancer. The second driver is my desire to fulfill what I call an alter ego duty of providing other individuals with help through a combination of medical knowledge and compassion.”
In some ways, these two psychological drivers are not mutually exclusive, according to Dr. Goulart. They interact with each other. In more recent years, however, his interest in biology of cancer has shifted towards the impact of cancer on social and economic domains of society. “And that actually motivates me even more to continue to provide cancer care to patients.”
Since medical school, Dr. Goulart’s interest in oncology came from a sense of curiosity and fascination about the biology of cancer and the potential of cancer as a model for clinical research that actually helps patients in serious situations.
“As I became closer to graduate as a physician, more and more I realized that this scientific interest for cancer was only one of the reasons to pursue a career in oncology. In reality, my foremost motivation to treat cancer is to be part of a physician-patient-family relationship at a critical time in the lives of these people,” Dr. Goulart says. “This is actually a challenging profession, where decisions often have a huge weight on patients’ lives. But despite this challenge, the contact with cancer patients is very special because it always reminds us of the inherent value of life, and this makes every single day, every single patient encounter worthy, and I look forward to it.”
Dr. Goulart’s research is in the field of outcomes research and pharmacoeconomics of cancer therapies, with a particular focus on lung and head and neck cancers.
“Most of my research activities involve comparisons of treatments in ‘real-world’ settings and their impact on survival and costs through the use of national, large retrospective databases,” Dr. Goulart says. “I also design and conduct large retrospective studies that assess the quality of cancer treatments delivered nationwide, and economic modeling of cost-effectiveness of cancer therapies and predictive genomic tests in lung cancer, including EGFR and ALK mutation testing.”
In his lifetime, Goulart hopes that diagnostic procedures for cancers will become less morbid for patients.
“For example, if a new blood test proves to be an accurate diagnostic test for a particular cancer, then we may be able to spare patients from inconvenient diagnostic procedures such as a tumor biopsy. Such advances may also reduce the overall costs of cancer care as well, both for patients and society in general,” he says.
In terms of treatment, Dr. Goulart hopes that the trends to molecularly targeted treatments will continue to advance, and that agents that are much more effective against each small subtype of cancer will be developed to help physicians tailor treatments for particular patients better, while sparing other patients from potential toxic effects and costs caused by otherwise ineffective or marginally effective therapies.
“This change in treatment paradigm has only now started to become reality,” Dr. Goulart says. “And I hope that in future years all cancer patients will have access to individualized and effective therapies that may even cure some cancers. I warn patients, however, that the advent of new and effective cancer drugs currently comes at very high costs, now higher than ever before. Therefore, the challenge for the future is to continue to provide patients with innovative, effective therapies that are affordable to patients and society.”
In general, Dr. Goulart hopes to see that through continuous educational efforts, healthier behaviors by individuals in our society will start to have an effect on public health, including changes in behaviors that can dramatically reduce the incidence of cancer, such as smoking cessation/prevention, balanced diet, weight control, appropriate sun exposure, and limited alcohol consumption.
Outside of work, Dr. Goulart enjoys exercising. He tries to run five miles at least twice a week. When time allows, he’ll lift weights. “One of my favorite activities in weekends or vacations is traveling and/or camping in areas of wildlife, such as the North Cascades, Olympic Peninsula, and in national parks,” he says. “Otherwise, I like to spend time relaxing and reading with my fiancé. Having said that, I accomplish a lot of computer work at different coffee shops, usually accompanied by a large iced Mocha.”
Bernardo H. L. Goulart, MD, MSDr. Goulart treats patients for lung cancer and head and neck cancers. He is also board certified in Internal Medicine.
Patient Care Philosophy:
Our main job as oncologists is to provide patients with the most accurate and clear information about their disease prognosis and treatment options, thereby enabling patients to actively participate in treatment decisions. Appropriately informed patients are in the best position to make treatment decisions that reflect their core values and beliefs, which is the ultimate definition of good quality care. Although accurate information is vital to good care, I also consider as one of my top responsibilities communicating with patients in a compassionate and respectful way, since many patients diagnosed with cancer are experiencing intense physical and personal changes that may deeply affect their lives and the lives of their families and loved ones.
- Affiliate Investigator, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Acting Instructor, University of Washington School of Medicine
Thoracic oncology; Head and Neck cancers
- Three-year residency, Medical Oncology, Brazilian National Cancer Institute; 2000 to 2003
- Four-year fellowship, Medical Oncology, University of Washington (thoracic oncology, head and neck cancers, and also in general oncology)
- Two-year residency, Internal Medicine, Federal University of Rio de Janeiro, Brazil
- Two-year residency, Internal Medicine, University of Washington
Education And Training
- Medical Education: Federal University of Rio de Janeiro, MD, 1997
- Master of Science: University of Washington, MS, 2010
- Fellowship: Medical Oncology, University of Washington, 2007-2011
- Residency: Internal Medicine, Federal University of Rio de Janeiro, 1998-2000
- Residency: Medical Oncology, Brazilian National Cancer Institute, 2000-2003
- Other notable training: Fellowship in Outcomes Research, Massachusetts General Hospital, 2003-2005
Board certified Internal Medicine
Bernardo H.L. Goulart. and Ramsey, Scott. “A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy Versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer.” Value in Health. In Press. http://www.valueinhealthjournal.com/inPress
Bernardo H.L. Goulart, Jeffrey Clark, Gregory Y. Lauwers, David P. Ryan, Nina Grenon, Alona Muzikansky, and Andrew X. Zhu. "Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis." Journal of Hematology & Oncology. www.jhoonline.org/content/2/1/13
Bernardo H.L. Goulart. “Trends in the Use and Role of Biomarkers in Phase I Oncology Trials.” Clinical Cancer Research. http://clincancerres.aacrjournals.org/content/13/22/6719.long
Bernardo H.L. Goulart, Renato G. Martins, Thomas J. Lynch."Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results." Journal of Clinical Oncology. http://jco.ascopubs.org/content/19/20/4089.1.long
Interview: “Meet the fellows” – round table at the 2011 National Comprehensive Cancer Network conference, March 9th 2011 www.cvent.com/events/nccn-academy-for-excellence-leadership-in-oncology/event-summary-5eb8ec1bb758434a82568ef323b13e20.aspx